Valuentum Exclusive Analysis for the Discerning Investor

Catching the Bottom?
Image shown: The depths of how far the S&P 500 (SPY) has fallen more recently, and the timing of the decision to move to being "fully invested" in simulated Best Ideas Newsletter portfolio and simulated Dividend Growth Newsletter portfolio. No Changes to Simulated Newsletter portfolios. This article was sent to members via email January 9.

Jan 4, 2019

Markets Up Big; Upside Volatility
Image shown: The S&P 500 ETF (SPY) since August 2017. The index has broken through support and is now bouncing back to resistance.

Mar 15, 2018

Cigna, Express, and the Unwinding of the PBM Market
Image Source: Cigna. Given its track record of creative destruction, when Amazon plans to enter a particular line of business, it presents an ominous threat to incumbents. What is often overlooked, too, is that Amazon is more than willing to try new verticals—if they prove promising, additional assets will be devoted to the new line of business, often with fawning media coverage. If Amazon is unsuccessful in its endeavor, however, then it seems as though it will “fail fast” and shut down the project and move on. We found the recent announcement of a joint venture to tackle the healthcare industry as particularly noteworthy.

Oct 31, 2017

CVS Health Under Review – Hit by a Storm of Negativity
Image Source: Mike Mozart. We are putting the fair value estimate of CVS Health under review while we re-evaluate the competitive environment and reassess the company’s appetite for leverage, which could impact dividend health.

May 31, 2017

Nevro: An Exciting But Risky Medtech Idea in the Early Stages of Its Growth
Image Source: Nevro. Innovation continues to thrive in the medical field. The rapid aging of the industrialized world’s population bodes well for rising demand. Let’s look at a promising med tech idea, which we believe offers explosive growth in the field of Neuromodulation. It's a risky one though.

Apr 4, 2017

Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?

Dec 7, 2016

Valuentum Weekly Web Commentary
Let’s take a look at some of the Valuentum Team’s commentary from the past week.

Nov 16, 2016

Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.

Aug 27, 2014

Tiffany Dazzles in Second Quarter; Coach Now Yielding ~4%
Tiffany’s second-quarter results were sparkling. Let’s take a deep dive and bring Coach to your attention.

Jan 27, 2014

Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space .

Valuentum Exclusive Analysis for the Discerning Investor Symbol Keyword

Member Login

Newsletters/Portfolios

Dividend Cushion

Stock Screens

Products & Tools

Value Trap

The Buying Index, VBI

Dividend Changes

Valuentum Exclusive Analysis for the Discerning Investor